Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab

20Citations
Citations of this article
37Readers
Mendeley users who have this article in their library.

Abstract

OBJECTIVE: To describe the disease course of carryover progressive multifocal leukoencephalopathy (PML) after switching from natalizumab to ocrelizumab in 2 patients with relapsing-remitting MS. METHODS: Two case reports with 1 year of follow-up and retrospective longitudinal measurements of serum neurofilament light (NfL) levels and B-cells. RESULTS: PML was diagnosed 78 days (case 1) and 97 days (case 2) after discontinuation of natalizumab. Both patients developed mild immune reconstitution inflammatory syndrome (IRIS) despite B-cell depletion caused by ocrelizumab. NfL levels increased in both patients during PML-IRIS. PML-IRIS lesions stabilized after treatment with mefloquine and mirtazapine, followed by methylprednisolone, and both patients continued therapy with ocrelizumab when B-cells started to repopulate. CONCLUSIONS: The clinical course of carryover PML was mild in both patients, suggesting that B-cell depletion possibly did not aggravate PML-IRIS in these 2 patients.

Cite

CITATION STYLE

APA

Toorop, A. A., van Lierop, Z. Y. G., Strijbis, E. E. M., Teunissen, C. E., Petzold, A., Wattjes, M. P., … Killestein, J. (2021). Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab. Neurology(R) Neuroimmunology & Neuroinflammation, 8(1). https://doi.org/10.1212/NXI.0000000000000904

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free